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Abstract
We present immunological data from two clinical trials where the effect of experimental human hookworm (Necator
americanus) infection on the pathology of celiac disease was evaluated. We found that basal production of Interferon- (IFN-)c
and Interleukin- (IL-)17A from duodenal biopsy culture was suppressed in hookworm-infected participants compared to
uninfectedcontrols.Increased levels ofCD4+CD25+Foxp3+ cellsinthecirculationand mucosaareassociatedwithactive celiac
disease. We show that this accumulation also occurs during a short-term (1 week) oral gluten challenge, and that hookworm
infection suppressed the increase of circulating CD4+CD25+Foxp3+ cells during this challenge period. When duodenal
biopsies from hookworm-infected participants were restimulated with the immunodominant gliadin peptide QE65, robust
production of IL-2, IFN-c and IL-17A was detected, even prior to gluten challenge while participants were strictly adhering to a
gluten-free diet. Intriguingly, IL-5 was produced only after hookworm infection in response to QE65. Thus we hypothesise that
hookworm-induced TH2 and IL-10 cross-regulation of the TH1/TH17 inflammatory response may be responsible for the
suppression of these responses during experimental hookworm infection.
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Introduction
Celiac disease is an immune-mediated intestinal inflammatory
condition. Uniquely to inflammatory gastrointestinal disease, the
stimulatory antigen (dietary gluten) and even the MHC restriction
are known [1]. As such, the immunopathology of celiac disease is
well understood and allows researchers to focus on the specific
population of CD4
+ T cells that are responsible for inflammation.
Predisposition to celiac disease is believed to depend on multiple
genetic, immunological and environmental factors [2]. Once the
disease is established, however, the processes that lead to
pathology are relatively well understood. Dietary gluten is broken
down into gliadin in the gut lumen; gliadin is then taken up by the
gut epithelium and processed by tissue transglutaminase (tTG) into
deamidated gliadin. Expression of tTG is upregulated by the
presence of gliadin and in active celiac disease patients produce
diagnostic autoantibodies to tTG [3]. Thus, celiac disease is often
referred to as an autoimmune disease, as it has autoimmune
components, despite the causative agent being ‘‘non-self’’.
Deamidated gliadin peptides bind strongly to HLA-DQ2 or
HLA-DQ8 MHC molecules, allowing efficient presentation to
CD4+ T cells, and indeed the presence of these MHC haplotypes
is the most important genetic risk factor predisposing to disease
[4].
Celiac disease has long been thought of as a purely T helper
type 1 (TH1) disease, but recent data suggests a role for TH17 cells
[5,6]. Inducing a switch from TH1/TH17 to TH2 has been
proposed as a potential treatment for celiac disease [7]. Regulatory
T cells (Tregs) also have a role in celiac disease, with recent studies
showing increased numbers of circulating and mucosal
CD4+Foxp3+ cells in individuals with active celiac disease, as
compared to those on a gluten-free diet [8,9].
Inflammatory gut conditions such as celiac disease are on the
rise in the developed world, and one proposed explanation for this
is the hygiene hypothesis. This proposes that as populations
become more hygienic with a lower incidence of childhood
infections (especially parasitic infections), there is a concurrent
increase in inappropriate and pathogenic immune responses
resulting in increased incidence of allergy, autoimmune and
inflammatory gut conditions [10–16]. Intervention studies, where
populations in developing country settings are treated for parasitic
infection using anthelmintic drugs, have also provided evidence for
the role of parasites, particularly hookworm [13,17,18], in
suppression of allergic responses.
Several clinical trials have been conducted using live parasite
infections to treat inflammatory bowel diseases and allergies.
These include clinical trials using Trichuris suis (pig whipworm) to
treat Crohn’s disease and ulcerative colitis, with reports of
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allergic rhinitis, however, have shown no beneficial effect of T. suis
[22]. We previously carried out an open label trial using the
human hookworm Necator americanus in Crohn’s disease and
observed a trend for reduction in symptom severity [23]. N.
americanus has also been used in a placebo-controlled clinical trial
in an attempt to suppress immunopathology in seasonal asthma
however there was no significant benefit in the parasite-infected
group compared to the control group [24].
We recently completed a placebo-controlled, double blinded
trial exploring the effect of experimental N. americanus infection as a
treatment for celiac disease [25]. In this trial, 20 subjects, all on a
strict gluten-free diet and in remission, were randomly assigned to
infection with 15 N. americanus larvae (hookworm group) or left
uninfected (control). After 20 weeks, both groups were subjected to
an oral gluten challenge. Here we present immunological data
from this trial (trial 1), and from a continuation of the trial (trial 2)
where 7 members of the control group were infected with N.
americanus, and their responses to a replicate gluten challenge
followed. As reported previously [25] no significant reductions in
symptom severity were seen in either trial. However, we
hypothesised that hookworms suppressed gluten-induced inflam-
matory immune responses and induced regulatory responses, but
this suppression may have been too subtle to lead to significant
suppression of pathology in this short-term, small-scale trial. We
found that basal TH1 and TH17 responses in the duodenum were
suppressed in hookworm-infected participants, and investigated
possible mechanisms of immune suppression.
Materials and Methods
Clinical Protocol – Trial 1
The design and clinical results of the placebo-controlled clinical
trial using hookworm to treat celiac disease have been described
elsewhere [25]. This was registered as a clinical trial at
ClinicalTrials.gov as NCT00671138. Briefly, twenty otherwise
healthy people with HLA-DQ2+ celiac disease on a long-term
gluten-free diet were recruited, randomised into 2 groups and
either infected percutaneously with 10 infective larvae (L3) of N.
americanus larvae (‘‘hookworm’’ group) or given placebo infection
using topical chilli pepper (‘‘control’’ group). Twelve weeks later a
boost infection of a further 5 infective larvae (or placebo) was
administered. At week 20 post-infection, all subjects were subject
to a gluten challenge consisting of four slices of white bread per
day for 5 days. This trial will herein be referred to as ‘‘trial 1’’.
Clinical Protocol - Trial 2
Approximately 1 year after the completion of trial 1, seven of the
ten control subjects participated in a second trial: two subjects could
not participate due to other commitments, and one was ineligible due
to raised tTG. These 7 participants were infected with N. americanus,
boosted and challenged with gluten in an identical manner to that
described for trial 1. This trial will herein be referred to as ‘‘trial 2’’.
Blood and Duodenal Biopsies
To examine the immune response to gluten, duodenal biopsies
were taken at weeks 20 (pre-gluten challenge) and 21 (post-gluten
challenge) in trial 1, and weeks 0 (pre-infection), 20 and 21 in trial
2. Blood was collected by venepuncture at weeks 0, 20 and 21 in
both trials.
Immunohistochemistry
Duodenal biopsies were fixed in formalin then sectioned for
immunohistochemical staining with anti-foxp3 antibodies
(eBioscience). Slides were assessed by counting positive cells in a
square field of view (FOV), 200 mm by 200 mm. Counts were
carried out in a blinded fashion by two independent researchers.
Acquisition of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinised blood over a Ficoll-Paque Plus gradient (GE
Healthcare). After separation, PBMCs were counted, and viability
was determined by Trypan blue exclusion (.95%). For flow
cytometry, PBMCs were frozen in 10% DMSO in fetal calf serum
(FCS - Invitrogen); samples from all time-points in each trial were
thawed and analysed simultaneously. Cells were stained with anti-
CD4-APC, -CD8-PE and -CD25-FITC antibodies (BD Biosci-
ences) then permeabilized and stained with anti-Foxp3-PerCP-
Cy5.5 using the Foxp3 kit (Ebioscience) according to manufac-
turer’s protocols. Relevant isotype controls were used for all flow
cytometry applications. Flow cytometry was performed using a
FACSCalibur or FACSCanto (BD Biosciences).
Biopsy culture and analysis
For ex vivo flow cytometry, four endoscopic pinch biopsies (each
approximately 8 mm
3) from the mid-duodenum were digested for
30 min at room temperature in 0.5 mg/ml collagenase I
(Invitrogen), before being passed through a 100 mm nylon filter,
yielding 1–2610
6 cells. Cells were then stained for CD4, CD8,
CD25 and Foxp3 as described above. For biopsy culture, whole
biopsies were placed in wells of a 24-well microtiter plate
containing 500 ml Tissue Culture Medium (TCM): RPMI-1640
medium (Invitrogen), 10% FCS, 100 U/ml penicillin, 100 mg/ml
streptomycin and 2 mM L-glutamine alone or TCM containing
50 mg/ml QE65 peptide (the dominant HLA-DQ2 gliadin peptide
[26]), and cultured for 24 h in 95% O2/5% CO2 at 37uC. Cell-
free supernatants were then taken for cytokine bead array (CBA,
BD Biosciences) analysis.
Statistical analysis
All analyses were carried out using Prism 4.0 (Graphpad). When
comparing groups and timepoints, where all data was available
from both groups (each group n=10), two-way ANOVA was used
with a Bonferroni’s post-test to compare timepoints between
groups. Where not all data from both groups was available, one-
way ANOVA and Bonferroni’s post test was used to compare
groups and timepoints. When comparing two different timepoints
within a group, t tests were used, and where comparing more than
2 timepoints within a group, one-way ANOVA was used. Data
was log transformed to normalise distributions where necessary.
Results
Cytokine production by duodenal biopsies
We assessed the inflammatory cytokine response in the
duodenum in trial 1 by measuring cytokine levels in supernatants
from whole duodenal biopsy cultures taken pre- or post-gluten
challenge. Levels of all cytokines assessed were low (,50 pg/ml) as
cells were not stimulated ex vivo. Levels of the TH1 cytokine IFN-c
and the TH17 cytokine IL-17A tended to increase after gluten
challenge in the control group only, but this change did not reach
statistical significance. However, levels of IFN-c and IL-17A were
significantly decreased in the hookworm-infected group compared
to the control group after gluten challenge (Figure 1A and B).
Systemic regulatory immune responses
Levels of CD4, CD8, CD25 and Foxp3 were assessed in
PBMCs taken from participants before and after gluten challenge.
Hookworm Suppresses Celiac Immune Responses
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in the overall proportion of circulating CD4
+ T cells (control
p=0.018, hookworm p=0.22) (Figure 2A), a trend for increased
proportions of CD25+Foxp3+ CD4
+ cells (control p=0.055,
hookworm p=0.24) (Figure 2B) and increased CD25 (Figure 2C)
and Foxp3 (Figure 2D) expression (MFI) in the CD4+CD25+
Foxp3+ population (p=0.016 and p=0.007 respectively), while
no change was seen in the hookworm group (p=0.69 and p=0.88
respectively). Representative plots are shown in Figure 2E.
Consistent with these results, when control individuals were
infected with hookworm and re-challenged with gluten in trial 2,
no changes were seen in any of the above measurements (CD4+ %
of lymphocytes pre-challenge 23.59+/211.88, post-challenge
23.77+/27.79 (p=0.92); CD25+Foxp3+ % of CD4+ pre-
challenge 0.65+/20.25, post-challenge 0.70+/20.28 (p=0.47);
CD25 MFI in CD4+CD25+Foxp3+ cells pre-challenge 864.4+/
258.3, post-challenge 837.4+/298.9 (p=0.25); Foxp3 MFI in
CD4+CD25+Foxp3+ cells pre-challenge 5900+/2437.9, post-
challenge 6094+/2695.6 (p=0.34) (mean +/2 SD)).
When cells isolated from duodenal biopsies were stained for
CD4, CD8, CD25 and Foxp3, a trend for increased proportions of
Foxp3+ cells were again seen in the CD4+ population, however in
contrast to the PBMC results, this was seen to an equal degree in
both groups, and did not reach significance (Figure 2F). In trial 2,
however, this increase in proportions of Foxp3+ cells within the
CD4+ population reached significance (pre-challenge 1.70+/
20.80, post-challenge 7.74+/23.37 (p=0.0014)).. Formalin fixed
biopsy sections from trial 1 were stained by immunohistochemistry
for Foxp3, confirming flow cytometry data showing that gluten
challenge increased numbers of Foxp3+ cells in both groups
(Figure 2G).
Mucosal Immune Response against QE65
To assess the gliadin-specific immune response in the mucosa
before (week 0) and after (week 20) hookworm infection and after
gluten challenge (week 21), duodenal biopsies from trial 2 were
cultured in either medium alone or QE65 peptide, and
supernatants were assessed for cytokine production. As shown in
Figure 3A, prior to infection or challenge highly significant levels
of IL-2 were produced upon stimulation with QE65 compared to
medium alone. There was also an apparent IFN-c and IL-17A
response to QE65 although these failed to reach statistical
significance (p=0.053 and p=0.073 respectively). No significant
levels of other cytokines were produced in response to QE65 at this
timepoint.
To investigate changes in cytokines produced in response to
QE65 over the course of the trial, cytokine levels produced in
response to medium alone for each individual were subtracted
from those produced in response to QE65, as shown in Figure 3D–
I. Levels of QE65-specific IL-2, IFN-c or IL-17A did not appear to
change after hookworm infection or challenge. Production of the
regulatory cytokine IL-10 in response to QE65 was significantly
increased after gluten challenge, however a small trend for
increased levels after challenge, prior to infection, was also seen
(Figure 3G). A significant increase in IL-5 produced in response to
QE65 was seen after hookworm infection (week 20), with a non-
significant trend for increased production of IL-13 (Figure 3H and
I). Levels of IL-4 produced following QE65 exposure were below
the level of detection (data not shown).
Discussion
As we recently demonstrated, hookworm administration in
celiac disease did not result in a clinically significant suppression of
pathology, although a trend towards reduced mucosal inflamma-
tion (as assessed by histological scoring) was seen with hookworm
infection after gluten challenge [25]. The infective dose of
hookworms used in our trial was low (a total of 15 larvae), which
although a safe dose [27], may be insufficient to effectively
suppress the immunopathogy of celiac disease.
Surprisingly however, we detected suppression of the basal
inflammatory immune response in hookworm infected subjects,
reflected in the suppression of duodenal IFN-c and IL-17A
production in trial 1. To extend these results, we developed a
biopsy restimulation assay for use in trial 2, using the purified
QE65 peptide to stimulate gliadin-specific T cells [26]. This
allowed us to avoid the use of commercial gliadin preparations
containing multiple epitopes, toxic factors and potential endotoxin
contamination, which may mask the gliadin-specific T cell
response [28]. Using this system we detected robust production
of IL-2 to QE65 prior to gluten challenge or infection, and strong
trends for production of IFN-c and IL-17A produced in response
Figure 1. Biopsies taken pre-challenge (week 20) and post-challenge (week 21) from trial 1 and were cultured for 24 hours in tissue
culture medium, then supernatants taken for CBA analysis of IFN-c (A) and IL-17A (B). One-way ANOVA was carried out comparing
between groups and timepoints. Unless otherwise indicated differences are not significant. **=p,0.01, *=p,0.05.
doi:10.1371/journal.pone.0024092.g001
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together, then stained for CD4, Foxp3 and CD25. Proportions of CD4
+ cells in the PBMC lymphocyte population (A). Proportions of
CD25
+Foxp3
+ cells in CD4
+ population (B). CD25 MFI (C) and Foxp3 MFI (D), both in the CD4
+CD25
+Foxp3
+ population. Representative Foxp3 versus
CD25 plots of cells gated on CD4+ PBMCs are shown in (E). Cell suspensions were prepared from duodenal biopsies pre-challenge and post-
challenge, and stained for CD4 and Foxp3. Foxp3+ proportion of the CD4+ population of biopsy cells (F). Formalin fixed duodenal biopsies were also
stained for Foxp3 by immunohistochemistry, Foxp3+ cells per high-power field of view (G). Where paired data was available (all except (F)), data were
analysed by two-way ANOVA, and if a significant interaction was found paired t tests were used to show differences within groups. For (F), data were
analysed by non-parametric ANOVA. N.S.=not significant, *=p,0.05, **=p,0.01.
doi:10.1371/journal.pone.0024092.g002
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cells reside in the duodenal mucosa, even after .6 months of
apparent strict adherence to a gluten-free diet. QE65-specific
responses did not appear to be suppressed by hookworm infection,
indicating that QE65-specfic T cell responses may remain high
during low intensity hookworm infection, while basal inflamma-
tory cytokine production is suppressed.
As candidate mechanisms for suppression of inflammatory
immune responses, we proposed IL-10 production, Treg expan-
sion or activation, and cross-regulation or skewing of the
inflammatory immune response to a TH2 response. While we
did not detect increased basal IL-10 production by duodenal
biopsy cells, we observed IL-10 production after gluten challenge
in the hookworm-infected participants in trial 2 in response to
QE65; there was also a trend for elevated IL-10 production after
hookworm infection but prior to gluten challenge. Therefore
hookworm infection may be inducing IL-10, which in turn is
suppressing the TH1/TH17 response, however a larger study is
required to confirm the existence of a pre-gluten challenge IL-10
response. Of note however, the production of IL-10 (along with
IFN-c) in the duodenum during active celiac disease has been
reported elsewhere [29], indicating that the post-challenge IL-10
production may be part of a normal celiac response.
Another candidate mechanism for immunomodulation ob-
served in helminth infections is Treg induction. In mouse models,
Tregs are induced by helminth infection [30–32], and are
responsible for controlling immunopathology [33]. Using Foxp3
as a marker of Tregs, we showed that gluten challenge induces an
expansion of mucosal Foxp3+ cells in celiac sufferers irrespective
of their hookworm infection status. We also show that in the
control, but not the hookworm-infected group, the proportion of
CD25+Foxp3+ cells in the circulating CD4+ population increased
after gluten challenge, and these cells had increased expression of
Foxp3 and CD25. In two recent studies comparing celiac sufferers
with active or treated disease, levels of CD4+CD25+Foxp3+ cells
in the blood were higher during active disease [8,9], however this
is the first time this effect has been shown during a controlled,
short-term gluten challenge. These results, and those from other
studies of Tregs in immunopathology [34,35] and surgical
inflammation [36], indicate that CD4+Foxp3+ cells often
accumulate during inflammation, however they may not be
functionally suppressive [36]. The suppression of effector T cells
by regulatory T cells may be rendered unsuccessful due to
upregulation of the negative regulator of TGF-b signalling Smad-7
[37]. Therefore counter-intuitively CD4+Foxp3+ cell levels in
chronic inflammatory diseases correlate with severity of disease,
Figure 3. Duodenal biopsies were taken from trial 2 participants pre-infection (Pre-Inf, week 0), pre-challenge (Pre-Ch, week 20)
and post-challenge (Post-Ch, week 21) and cultured in either medium alone or with 50 mg/ml QE65 peptide for 24 hours at 376Ci n
95% O2/5% CO2. Supernatants were then taken and levels of cytokines measured by CBA. Results shown in A–C are from the pre-infection
timepoint only, showing both medium and QE65 levels. All other results (D–I) have had medium controls subtracted. Cytokines shown are IL-2 (A, D),
IFN-c (B, E), IL-17A (C, F), IL-10 (G), IL-5 (H) and IL-13 (I). A–C was analysed by paired t tests, D–I by 1-way ANOVA. Where data was not normally
distributed, log-transformation was carried out and parametric tests used. Differences are not significant unless indicated. *=p,0.05, **=p,0.01.
doi:10.1371/journal.pone.0024092.g003
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intriguing possibility that the Foxp3+ cells in the mucosa may also
be producing IL-17, and so may not be fully committed to either
the TH17 or Treg phenotypes [38]. Unfortunately functional
assays of CD4+Foxp3+ suppression were not within the scope of
this study, so we cannot say whether the hookworm infection
increased suppressive ability and so suppressed inflammatory
cytokine production.
We propose that hookworm infection skews the celiac immune
response towards a TH2 phenotype, cross-regulating the inflam-
matory TH1/TH17 response. When duodenal biopsy cultures
from trial 2 were restimulated with QE65 peptide, we found no
evidence of a TH2 response prior to infection but we did observe
significantly increased production of IL-5 (and a trend for
increased production of IL-13) to QE65 once the hookworm
infection had become patent. This suggests that the anti-gluten
response is being skewed away from a TH1/TH17 towards a TH2
phenotype as a consequence of the immune response to hookworm
infection. TH2 responses are often associated with IL-10
production, which in turn suppresses inflammatory responses
[39]. Evidence for established inflammatory responses being
suppressed by TH2 responses comes from coinfection studies,
for instance established Bordetella pertussis-inducedTH1 responses
can be suppressed by Fasciola hepatica TH2 responses in an IL-4-
dependent manner [40]. Indeed, skewing of the immune response
towards TH2 in celiac disease has been suggested previously as a
potential immunotherapy [41].
In summary, we present immunological data from a clinical trial
using human hookworm to treat celiac disease. We cultured
intestinal biopsies in a gliadin-derived peptide and found
inflammatory T cell responses could be measured in the absence
of in vivo gluten challenge, and that even short term gluten
challenge increased the levels of CD4+Foxp3+ cells in celiac
individuals. Hookworm infection suppressed basal production of
the inflammatory cytokines IFN-c and IL-17A, and our data
indicate that this suppression may be dependent upon skewing or
cross-regulation of the celiac response by a concurrent TH2
response, and/or IL-10 production. Future efforts should explore
the potential protective effect of hookworm on a lesser gluten
challenge than that used in this study, addressing the impact of
infection on a low gluten diet.
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